Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-27
2005-09-27
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S085700, C435S455000
Reexamination Certificate
active
06949520
ABSTRACT:
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
REFERENCES:
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5248670 (1993-09-01), Draper et al.
patent: 5359052 (1994-10-01), Stee et al.
patent: 5512668 (1996-04-01), Stec et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5635363 (1997-06-01), Altman et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5786189 (1998-07-01), Locht et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5856465 (1999-01-01), Stec et al.
patent: 5883237 (1999-03-01), Stec et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 2002/0091097 (2002-07-01), Bratzler et al.
patent: 2002/0164341 (2002-11-01), Davis et al.
patent: 2002/0165178 (2002-11-01), Schetter et al.
patent: 2002/0198165 (2002-12-01), Bratzler et al.
patent: 2003/0026801 (2003-02-01), Weiner et al.
patent: 2003/0050261 (2003-03-01), Krieg et al.
patent: 2003/0050263 (2003-03-01), Krieg et al.
patent: 2003/0050268 (2003-03-01), Krieg et al.
patent: 2003/0055014 (2003-03-01), Bratzler
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0100527 (2003-05-01), Krieg et al.
patent: 2003/0104523 (2003-06-01), Lipford et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2003/0148316 (2003-08-01), Lipford et al.
patent: 2003/0148976 (2003-08-01), Krieg et al.
patent: 2003/0166001 (2003-09-01), Lipford
patent: 2003/0181406 (2003-09-01), Schetter et al.
patent: 2003/0191079 (2003-10-01), Krieg et al.
patent: 0302758 (1989-02-01), None
patent: 0174143 (1989-11-01), None
patent: 0468520 (1992-01-01), None
patent: 0092574 (1992-04-01), None
patent: 0 855 184 (1998-07-01), None
patent: WO 91/12811 (1991-09-01), None
patent: WO 92/03456 (1992-04-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 92/21353 (1992-12-01), None
patent: WO 94/19945 (1994-09-01), None
patent: WO 95/05853 (1995-03-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/35782 (1996-11-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/14210 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO98/32462 (1998-07-01), None
patent: WO98/33517 (1998-08-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO98/55495 (1998-10-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO99/51259 (1999-10-01), None
patent: WO99/56755 (1999-11-01), None
patent: WO99/58118 (1999-11-01), None
patent: WO99/61056 (1999-12-01), None
patent: WO00/06588 (2000-02-01), None
patent: WO00/14217 (2000-03-01), None
patent: WO00/67023 (2000-11-01), None
patent: WO01/22972 (2001-04-01), None
patent: WO 02/069369 (2002-09-01), None
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-241.
Deonarain et al., Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents, vol. 8, pp. 53-69.
Miller et al., Targeted vectors for gene therapy, 1995, FASEB J, vol. 9, pp. 190-199.
Azad RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region.Antimicrob Agents Chemother.Sep. 1993;37(9):1945-54.
Azuma I, Biochemical and immunological studies on cellular components oftubercle bacilli. Kekkaku1992;67(9):45-55.
Bartholome EJ et al., Interferon-beta induce the maturation of IL-12-deficient myeloid dendritic cells able to induce Th2 type cytokine secretion.J Interferon Cytokine Res.1999;19(Suppl 1):S81.
Bayever E et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.Antisense Res Dev.1993 Winter;3(4):383-90.
Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA.J Clin Invest.Dec. 1985;76(6):2182-90.
Blaxter ML et al., Genes expressed inBrugia malayiinfective third stage larvae.Mol Biochem Parasitol.Apr. 1996;77(1):77-93.
Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides.Antisense Nucleic Acid Drug Dev.Oct. 1997;7(5):461-71.
Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides.J Lab Clin Med.Sep. 1996;128(3):329-38.
Branda RF et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1.Biochem Pharmacol.May 25, 1993;45(10):2037-43.
Cella M et al., Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.J Exp Med.Mar.1, 1999;189(5):821-9.
Chace JH et al., Regulation of differentiation in CD5+ and conventional B cells. Sensitivity to LPS-induced differentiation and interferon-gamma-mediated inhibition of differentiation.Clin Immunol Immunopathol.Sep. 1993;68(3):327-32.
Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements.J Virol.Jan. 1990;64(1):264-77.
Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.J Exp Med.Nov. 17, 1997;186(10):1623-31.
Crystal RG, Transfer of genes to humans: early lessons and obstacles to success.Science.Oct. 20, 1995;270(5235):404-10.
English U et al., Chemically modified oligonucleotides as probes and inhibitors.Angew Chemie Int Ed Engl.Jun. 1991;39(6):613-29.
Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia.J Exp Med.Feb. 16, 1998;187(4):561-9.
Etlinger HM, Carrier sequence selection—one key to successful vaccines.Immunol Today.Feb. 1992;13(2):52-5.
Ferbas JJ et al., CD4+ blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection.J Immunol.May 1, 1994;152(9):4649-62.
Gura T, Antisense has growing pains.Science.Oct. 27, 1995;270(5236):575-7.
Hadden JW et al., Immunopharmacology. Immunomodulation and immunotherapy.JAMA.Nov. 25, 1992;268(20):2964-9.
Hadden JW, Immunostimulants.Trends Pharmacol Sci.May 1993;14(5):169-74.
Hatzfeld J et al., Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides.J Exp Med.Oct. 1, 1991;174(4):925-9.
Highfield PE, Sepsis: the more, the murkier.Biotechnology(NY). Aug. 1994;12(8):828.
Iguchi-Ariga SM et al., CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation.Genes Dev.May 1989;3(5):612-9.
Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution.J Immunol.May 1, 1993;150(9):3713-27.
Iversen PL et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.Antisense Res Dev.1994 Spring;4(1):43-52.
Jakway JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products.J Immunol.Oct. 1, 1986;137(7):2225-31.
Jaroszew
Bratzler Robert L.
Hartmann Gunther
Krieg Arthur M.
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group, Inc.
Guzo David
Nguyen Quang
University of Iowa Research Foundation
LandOfFree
Methods related to immunostimulatory nucleic acid-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods related to immunostimulatory nucleic acid-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods related to immunostimulatory nucleic acid-induced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446762